Adial Pharmaceuticals, Inc. ADIL · Stock Open Adial Pharmaceuticals, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Adial Pharmaceuticals, Inc. Analysis (ADIL)
Is Adial Pharmaceuticals, Inc. a good investment? Adial Pharmaceuticals, Inc. (ADIL) is currently trading at 3.50 USD. Market analysts have a consensus price target of 8.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: Adial Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -7.45.
Investor FAQ
Does Adial Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Adial Pharmaceuticals, Inc.?
Adial Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -20.65.
Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 7, 2023 | 1:25 |
| Feb. 5, 2026 | 1:25 |
Community Discussion